<DOC>
	<DOCNO>NCT01910415</DOCNO>
	<brief_summary>This study design evaluate effect multiple dos lumacaftor combination ivacaftor cardiac repolarization , detect QT/QTc interval correct heart rate healthy subject .</brief_summary>
	<brief_title>Phase 1 , QT/QTC Interval Study Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Subjects must willing able comply schedule visit , treatment plan , lifestyle guideline , laboratory test , contraceptive guideline , study procedure . Subjects must healthy , define clinically relevant abnormality identify detailed medical history , physical examination , include blood pressure pulse rate measurement , 12 lead ECG . Subjects must weigh &gt; 50kg Abnormal renal function Screening Plasma donation within 7 day first study drug dose blood donation 1 pint ( 500mL ) within 56 day first study drug dose Positively screen Hepatitis B , Hepatitis C , HIV Known hypersensitivity prior adverse reaction moxifloxacin quinolones Any condition possibly affect drug absorption ( e.g. , gastrectomy , gastrointestinal tract surgery , except appendectomy cholecystectomy polypectomy ) regular use acidlowering therapy ( H2 blocker , proton pump inhibitor , antacid ) . Female subject pregnant , nursing , plan become pregnant study within 90 day last study drug dose female subject childbearing potential unwilling unable follow contraceptive guideline least 14 day first study drug dose . Male subject female partner pregnant , nursing , plan become pregnant study within 90 day last study drug dose ; male subject unwilling unable follow contraceptive guideline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>